Ozmosi | Glipizide Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Glipizide

Alternative Names: glipizide, glucotrol, glide, metaglip, glucotrol xl
Clinical Status: Inactive
Latest Update: 2025-12-09
Latest Update Note: News Article

Product Description

Glipizide belongs to a class of drugs called sulfonylureas. It stimulates the release of insulin from the pancreas, directing your body to store blood sugar. This helps lower blood sugar and restore the way you use food to make energy. (Sourced from: https://www.mayoclinic.org/drugs-supplements/glipizide-oral-route/side-effects/drg-20072046?p=1)

Mechanisms of Action: ABCC8 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Australia | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Czech | Denmark | Dominican Republic | Egypt | Estonia | France | Germany | Hong Kong | India | Indonesia | Ireland | Israel | Italy | Jordan | Latvia | Lithuania | Malaysia | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated